Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M

Monte Rosa Therapeutics, Inc.

Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.
Up to $5.7B in total milestone payments plus tiered royalties (high single to low double-digits) across up to three programs.
Novartis gets exclusive license to one undisclosed discovery target and options on two additional preclinical I&I programs.
Second collaboration with Novartis; first (VAV1/MRT-6160) was announced Oct 2024.
Extended cash runway accelerates preclinical and clinical-stage immunology pipeline; Phase 2 readouts expected for MRT-8102, MRT-6160, MRT-2359.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.